Ultrasound and diffuse optical tomography-transformer model for assessing pathological complete response to neoadjuvant chemotherapy in breast cancer.


Journal

Journal of biomedical optics
ISSN: 1560-2281
Titre abrégé: J Biomed Opt
Pays: United States
ID NLM: 9605853

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 23 04 2024
revised: 28 06 2024
accepted: 01 07 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: ppublish

Résumé

We evaluate the efficiency of integrating ultrasound (US) and diffuse optical tomography (DOT) images for predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients. The ultrasound-diffuse optical tomography (USDOT)-Transformer model represents a significant step toward accurate prediction of pCR, which is critical for personalized treatment planning. We aim to develop and assess the performance of the USDOT-Transformer model, which combines US and DOT images with tumor receptor biomarkers to predict the pCR of breast cancer patients under NAC. We developed the USDOT-Transformer model using a dual-input transformer to process co-registered US and DOT images along with tumor receptor biomarkers. Our dataset comprised imaging data from 60 patients at multiple time points during their chemotherapy treatment. We used fivefold cross-validation to assess the model's performance, comparing its results against a single modality of US or DOT. The USDOT-Transformer model demonstrated excellent predictive performance, with a mean area under the receiving characteristic curve of 0.96 (95%CI: 0.93 to 0.99) across the fivefold cross-validation. The integration of US and DOT images significantly enhanced the model's ability to predict pCR, outperforming models that relied on a single imaging modality (0.87 for US and 0.82 for DOT). This performance indicates the potential of advanced deep learning techniques and multimodal imaging data for improving the accuracy (ACC) of pCR prediction. The USDOT-Transformer model offers a promising non-invasive approach for predicting pCR to NAC in breast cancer patients. By leveraging the structural and functional information from US and DOT images, the model offers a faster and more reliable tool for personalized treatment planning. Future work will focus on expanding the dataset and refining the model to further improve its accuracy and generalizability.

Identifiants

pubmed: 39050779
doi: 10.1117/1.JBO.29.7.076007
pii: 240114GRR
pmc: PMC11268382
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

076007

Informations de copyright

© 2024 The Authors.

Références

Front Oncol. 2021 Dec 21;11:786346
pubmed: 34993145
J Natl Cancer Inst. 2008 Apr 16;100(8):552-62
pubmed: 18398094
Oncologist. 2017 Apr;22(4):394-401
pubmed: 28314842
Transl Oncol. 2018 Feb;11(1):56-64
pubmed: 29175630
Int J Cancer. 2015 Jun 1;136(11):2730-7
pubmed: 25387885
Ann Surg. 2021 Nov 1;274(5):713-720
pubmed: 34334656
Semin Oncol. 2001 Aug;28(4):389-99
pubmed: 11498832
Radiology. 2013 Feb;266(2):433-42
pubmed: 23264349
Clin Cancer Res. 2021 Apr 1;27(7):1949-1957
pubmed: 33451976
Clin Breast Cancer. 2019 Feb;19(1):71-77
pubmed: 30206035
Breast Cancer Res. 2014 Oct 28;16(5):456
pubmed: 25349073
Breast Cancer Res. 2018 Jun 14;20(1):56
pubmed: 29898762
Gynecol Oncol. 2016 Oct;143(1):3-15
pubmed: 27650684
Cancer. 2007 Dec 1;110(11):2394-407
pubmed: 17941030
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Thorac Cancer. 2020 Mar;11(3):651-658
pubmed: 31944571
Br J Cancer. 2017 May 9;116(10):1329-1339
pubmed: 28419079
Acad Radiol. 2023 Aug;30(8):1638-1647
pubmed: 36564256
Breast Cancer Res. 2020 Mar 13;22(1):29
pubmed: 32169100
Cancer Res. 2016 Oct 15;76(20):5933-5944
pubmed: 27527559
Oncologist. 2016 Aug;21(8):931-9
pubmed: 27401897
Radiology. 2018 Jun;287(3):778-786
pubmed: 29431574
Breast Cancer Res Treat. 2021 Aug;188(3):615-630
pubmed: 33970392
Am J Surg. 2010 Apr;199(4):477-84
pubmed: 20359567
J Nucl Med. 2016 Aug;57(8):1166-7
pubmed: 27103023
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Mol Imaging Biol. 2019 Feb;21(1):1-10
pubmed: 29516387
Clin Cancer Res. 2019 Jun 15;25(12):3538-3547
pubmed: 30842125
J Biomed Opt. 2018 Oct;24(2):1-11
pubmed: 30338678
Breast Cancer Res. 2022 Nov 21;24(1):81
pubmed: 36414984
Clin Cancer Res. 2014 Dec 1;20(23):6006-15
pubmed: 25294916
J Transl Med. 2021 Aug 16;19(1):348
pubmed: 34399795
Breast. 2018 Jun;39:19-23
pubmed: 29518677
IEEE J Biomed Health Inform. 2023 Jan;27(1):251-262
pubmed: 36264731
Sci Rep. 2021 Sep 22;11(1):18800
pubmed: 34552163

Auteurs

Yun Zou (Y)

Washington University in St. Louis, Department of Biomedical Engineering, St. Louis, Missouri, United States.

Minghao Xue (M)

Washington University in St. Louis, Department of Biomedical Engineering, St. Louis, Missouri, United States.

Md Iqbal Hossain (MI)

Washington University in St. Louis, Imaging Science, St. Louis, Missouri, United States.

Quing Zhu (Q)

Washington University in St. Louis, Department of Biomedical Engineering, St. Louis, Missouri, United States.
Washington University School of Medicine, Department of Radiology, St. Louis, Missouri, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH